List view / Grid view



Positive Phase 1b results for Heptares’ HTL9936

10 February 2016 | By Victoria White

HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia...

FDA approves schizophrenia treatment Aristada

7 October 2015 | By Victoria White

Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection...